symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
LGVN,1.87,0.726107,328182,39881303,0,1.5-4.579,-0.01,Longeveron Inc.,USD,0001721484,US54303L1044,54303L104,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.longeveron.com,"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.",Mr. Mohamed Wa'el Ahmed Hashad,Healthcare,US,19,305 909 0840,1951 NW 7th Avenue,Miami,FL,33136,,0,https://financialmodelingprep.com/image-stock/LGVN.png,2021-02-12,False,False,True,False,False
